Abeona Therapeutics (ABEO) Stock Analysis & AI Equity Report
Abeona Therapeutics (ABEO) overview
Abeona Therapeutics (ABEO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 5.8m and operating profit of USD -89.4m; the year-end share price was 5.27 USD and market capitalisation was USD 290m. Abeona Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Abeona Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Abeona Therapeutics
Abeona Therapeutics is a commercial-stage biopharmaceutical company developing treatments for rare and serious diseases. Its FDA-approved ZEVASKYN is an autologous gene-modified cell therapy for wounds in patients with recessive dystrophic epidermolysis bullosa. Its development portfolio includes ABO-701, an engineered T-cell therapy for solid tumors, and ABO-801, a Phase 3-ready oral fluticasone candidate acquired in November 2026 for eosinophilic esophagitis.
Generate the Abeona Therapeutics report
Abeona Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Abeona Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Abeona Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.